The advancement of computational chemistry is currently stalled by the exponential memory scaling required to simulate strongly correlated electron systems on classical supercomputers. This fundamental barrier significantly impedes the rational design of complex pharmaceuticals and next-generation catalytic materials. This research aims to rigorously validate the immediate utility of Noisy Intermediate-Scale Quantum (NISQ) processors, demonstrating that “Quantum Advantage” has shifted from a theoretical milestone to a practical industrial reality. We employed a comparative research design utilizing the Variational Quantum Eigensolver (VQE) algorithm on the IBM Eagle quantum processor. The study targeted the electronic structure of iron-sulfur clusters and KRAS-G12C inhibitor binding sites, benchmarking quantum outputs against classical Density Functional Theory (DFT) and Full Configuration Interaction (FCI) standards, utilizing Zero-Noise Extrapolation for error mitigation. Results indicate that quantum simulations achieved chemical accuracy (within 1.6 kcal/mol) for these complex systems, whereas classical methods failed with deviations exceeding 8 kcal/mol. The data confirms that quantum hardware can now resolve electronic correlations invisible to classical approximation. We conclude that quantum computing offers a tangible, immediate pathway to accelerate discovery cycles in drug development and material science, necessitating the integration of hybrid quantum workflows into modern R&D pipelines.